# A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer

> **NCT07673887** · PHASE3 · RECRUITING · sponsor: **Astellas Pharma Global Development, Inc.** · enrollment: 570 (estimated)

## Conditions studied

- Gastric Adenocarcinoma
- Gastroesophageal Junction (GEJ) Adenocarcinoma

## Interventions

- **DRUG:** ASP2138
- **DRUG:** Pembrolizumab
- **DRUG:** Oxaliplatin
- **DRUG:** Capecitabine
- **DRUG:** Folinic acid
- **DRUG:** 5-FU
- **DRUG:** Placebo for ASP2138
- **DRUG:** Placebo for Pembrolizumab

## Key facts

- **NCT ID:** NCT07673887
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-30
- **Primary completion:** 2031-02-28
- **Final completion:** 2031-02-28
- **Target enrollment:** 570 (ESTIMATED)
- **Last updated:** 2026-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07673887

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07673887, "A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07673887. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*